The choice of treatment for macular edema following retinal vein occlusion

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


A clinical efficacy assessment was performed for the therapy of post-occlusive cystoid macular edema using intravitreal anti-VEGF-ranibizumab injections at short and remote terms from the disease onset. It has been shown that ranibizumab intravitreal injections in retinal vein occlusion allow to increase visual acuity and to reduce retinal edema, and thus rehabilitate patients in maximally short terms. Intravitreal injections of vascular endothelial growth factor inhibitors at short terms from the disease onset allow achieving stabilization of the pathological process with preservation or improvement of visual functions, while reducing the number of repeated intravitreal injections.

Full Text

Restricted Access

About the authors

Larisa Konstantinovna Moshetova

Russian medical Academy of postgraduate education

Email: Moshetovalk@yandex.ru
MD, DMSc, professor, acad. RAN, Department of ophthalmology

Tat'yana Vyacheslavovna Tsikhonchuk

Russian medical Academy of postgraduate education

Email: tatiana_tsikhonchuk@yahoo.com
postgraduate student, Department of ophthalmology

Kseniya Ivanovna Turkina

Russian medical Academy of postgraduate education

Email: kseniyait@mail.ru
MD, candidate of medical science, Department of ophthalmology

Sergey Aleksandrovich Ignat'ev

Botkin clinical hospital, branch 1, оphthalmological hospital

Email: ignatievokb@gmail.com
candidate of medical science, ophthalmologist, head of policlinic

References

  1. Бойко Э. В., Сосновский С. В. Антиангиогенная терапия в офтальмологии. СПб: ВМА; 2013.
  2. Тульцева С. Н., Астахов Ю. С. Окклюзии вен сетчатки (этиология, патогенез, клиника, диагностика, лечение. СПб.: Н-Л.; 2010.
  3. Тульцева С. Н., Астахов Ю. С. Роль воспаления в патогенезе посттромботического макулярного отека, современные направления медикаментозного лечения. Офтальмологические ведомости. 2012; 5 (4): 35-42.
  4. Тульцева С. Н., Нечипоренко П. А., Титаренко А. И. Использование интравитреального имплантата «озурдекс» в терапии постокклюзионного макулярного отека. Офтальмологические ведомости. 2014; 7 (3): 5-16.
  5. Browning D. J., McOwen M. D., Bowen Jr R. M., O'Marah T. L. Comparison of the clinical diagnosis of diabetic macular edema with diagnosis by optical coherence tomography. Ophtalmology. 2004; 111: 712-5.
  6. Browning David J. Retinal Vein Occlusions: Evidence-Based Management. 2012; 265-75.
  7. Campochiaro P. A., Hafiz G., Shah S. M. et al. Ranibizumab for macular edema due to retinal vein occlusion: implication of VEGF as a critical stimulator. Mol. Ther. 2008; 16: 791-9.
  8. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophtalmology. 1995; 102 (10): 1425-33.
  9. Haller J. A. et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophtalmology. 2010; 117 (6): 1134-46.
  10. Ip M. S. et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion. The SCORE Study Research Group. Arch. Ophthalmol. 2009; 127 (9): 1101-14.
  11. Karia N. Retinal vein occlusion: pathophysiology and treatment options. Clin. Ophthalmol. 2010; 4: 809-16.
  12. Noma H., Funatsu H., Yamasaki M. et al. Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye (Lond). 2008; 22: 42-8.
  13. Noma H., Minamoto A., Funatsu H. et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch. Clin. Exp. Ophthalmol. 2006; 244: 309-15.
  14. Rogers S., McIntosh R. L., Cheung N. et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia and Australia. Ophthalmology. 2010; 117 (2): 313-9.
  15. Yoshimura T., Sonoda K. H., Sugahara M. et al. Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS ONE. 2009; 4 (12): 8158.

Statistics

Views

Abstract - 2317

PDF (Russian) - 644

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions


Copyright (c) 2015 Moshetova L.K., Tsikhonchuk T.V., Turkina K.I., Ignat'ev S.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies